Race Oncology Limited (ASX:RAC)

Market Cap	231.05M
Revenue (ttm)	5.25M
Net Income (ttm)	-7.65M
Shares Out	173.72M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	268,249
Average Volume	155,875
Open	1.410
Previous Close	1.330
Day's Range	1.335 - 1.490
52-Week Range	0.920 - 2.090
Beta	2.10
RSI	69.48
Earnings Date	May 26, 2025

About Race Oncology

Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RAC

Financial Performance

In 2024, Race Oncology's revenue was 4.00 million, an increase of 27.73% compared to the previous year's 3.13 million. Losses were -13.82 million, 39.3% more than in 2023.